Title
Ozone effects on blood biomarkers of systemic inflammation, oxidative stress, endothelial function, and thrombosis: The Multicenter Ozone Study in oldEr Subjects (MOSES).

Permalink
https://escholarship.org/uc/item/1vp1w6zh

Journal
PloS one, 14(9)

ISSN
1932-6203

Authors
Balmes, John R
Arjomandi, Mehrdad
Bromberg, Philip A
et al.

Publication Date
2019

DOI
10.1371/journal.pone.0222601

Peer reviewed
Abstract

The evidence that exposure to ozone air pollution causes acute cardiovascular effects is mixed. We postulated that exposure to ambient levels of ozone would increase blood markers of systemic inflammation, prothrombotic state, oxidative stress, and vascular dysfunction in healthy older subjects, and that absence of the glutathione S-transferase Mu 1 (GSTM1) gene would confer increased susceptibility. This double-blind, randomized, crossover study of 87 healthy volunteers 55–70 years of age was conducted at three sites using a common protocol. Subjects were exposed for 3 h in random order to 0 parts per billion (ppb) (filtered air), 70 ppb, and 120 ppb ozone, alternating 15 min of moderate exercise and rest. Blood was obtained the day before, approximately 4 h after, and approximately 22 h after each exposure. Linear mixed effect and logistic regression models evaluated the impact of exposure to ozone on pre-specified primary and secondary outcomes. The definition of statistical significance was $p < 0.01$. There were no effects of ozone on the three primary markers of systemic inflammation and a prothrombotic state: C-reactive protein, monocyte-platelet conjugates, and microparticle-associated tissue factor activity. However, among the secondary endpoints, endothelin-1, a potent vasoconstrictor, increased from pre- to post-exposure with ozone concentration (120 vs 0 ppb: 0.07 pg/mL, 95% confidence interval [CI] 0.01, 0.14; 70 vs 0 ppb: -0.03 pg/mL, CI -0.09, 0.04; $p = 0.008$). Nitrotyrosine, a marker of...
oxidative and nitrosative stress, decreased with increasing ozone concentrations, with marginal significance (120 vs 0 ppb: -41.5, CI -70.1, -12.8; 70 vs 0 ppb: -14.2, CI -42.7, 14.2; p = 0.017). GSTM1 status did not modify the effect of ozone exposure on any of the outcomes. These findings from healthy older adults fail to identify any mechanistic basis for the epidemiologically described cardiovascular effects of exposure to ozone. The findings, however, may not be applicable to adults with cardiovascular disease.

Introduction

Exposure to air pollution is a well-established risk factor for cardiovascular morbidity and mortality. Most of the evidence supporting an association between air pollution and adverse cardiovascular effects involves exposure to particulate matter [1]. Tropospheric ozone, formed when nitrogen oxides and volatile organic compounds react in the lower atmosphere in the presence of sunlight, is known to have acute respiratory effects, with decrements in lung function and increases in lung inflammation, respiratory symptoms, and respiratory mortality and morbidity [2–4]. Recent epidemiological studies have also linked ozone exposure with increased cardiovascular mortality and morbidity, although the evidence is mixed. For example, Bell et al. [5] reported a 0.64% increase in the risk of cardiovascular and respiratory mortality (95% confidence interval [CI] 0.31%, 0.98%) associated with each 10 parts per billion (ppb) increase in the previous week’s ozone concentration. However, Bravo et al. [6] found no such acute association between increased ozone concentrations and cardiovascular mortality in the population of Sao Paulo, Brazil. Some investigators have reported increased risks of cardiovascular and/or cerebrovascular hospital and emergency room admissions associated with increased ozone concentrations in the days before the event [7–13], while others have not [14–22]. Most of these studies examined associations between health outcomes and multiple ambient air pollutants.

Meta-analyses have concluded that increased ambient ozone concentrations are associated with an increased risk/rate of stroke [23], but not myocardial infarction or heart failure [24, 25]. However, the ozone effect estimates from these meta-analyses are generally similar in magnitude, with statistical significance reflecting in part the number of studies used. Thus, taken together, the meta-analyses appear to support a very small increased risk of acute cardiovascular events associated with increased ozone concentrations in the days before the event. Indeed, the 2013 Integrated Science Assessment for ozone prepared by the US Environmental Protection Agency (EPA) [26], concluded there is likely a causal relationship between short-term exposure to ozone and both total and cardiovascular mortality.

Controlled exposure studies at pollutant concentrations relevant to ambient concentrations can explore the mechanistic basis for the associations observed in epidemiological studies between short-term exposures to ozone and acute cardiovascular disease outcomes, and identify markers of effect that would be useful in future observational (e.g., panel) studies. Recently, two controlled human exposure studies [27, 28] in healthy young adults, at ozone concentrations sufficient to elicit changes in pulmonary function (100 ppb for 4 h and 300 ppb for 2 h, respectively, with intermittent exercise), found effects on systemic inflammation. However, Frampton et al. [29] found no effects of 3-h exposures to 100 and 200 ppb ozone, with intermittent exercise, on measures of systemic and pulmonary vascular function, impedance cardiography, blood microparticles, or blood platelet activation. Thus, findings from controlled human exposure studies on the cardiovascular effects of ozone are inconsistent, and there are...
no studies focusing on effects in older subjects. Aging increases the risk of cardiovascular disease and may alter acute cardiovascular responses to inhaled ozone.

We postulated that initial reactions of inhaled ozone with lipid substrates on airways surfaces generate a variety of reactive chemicals that activate multiple airway cells. Mediators released from these cells enter the circulation and may cause activation of blood elements, notably platelets, and increase the production of acute phase reactants such as C-reactive protein (CRP). Activated endothelial and blood cells also generate and release membrane-enclosed vesicles (microparticles) that contain a variety of biologically active intracellular molecules. Such vesicles may serve an endocrine-like function by adhering to other cells and transferring their contents (e.g., microparticle-associated tissue factor). These systemic changes could result in prothrombotic as well as other cardiovascular effects.

Given that ozone exposure generates oxidative stress, individuals with impaired anti-oxidant defenses may be at increased risk for acute health effects. Soluble cytosolic GSH transferases (GST) belong to a supergene family with multiple classes which might be involved in detoxification of post-exposure inflammation-related oxidants or in the resolution of inflammation. The GST Mu 1 (GSTM1) gene (reviewed by Wu et al.) [30] is particularly noteworthy because about half the Caucasian population is genetically null for this enzyme. A controlled human exposure study has shown an increase in the late airway inflammatory response to ozone in GSTM1-null subjects [31, 32]. Because a prolonged inflammatory response would increase oxidative stress, it is plausible that the GSTM1-null state might contribute to post-ozone exposure cardiovascular changes. However, studies on the role of GSTM1 on susceptibility to cardiovascular effects are few. A recent controlled ozone exposure study [29] in young healthy volunteers did not support a role of GSTM1 in eliciting cardiac and vascular function effects.

The Multicenter Ozone Study in oldEr Subjects (MOSES) was a controlled human exposure study in which we exposed a relatively large number of healthy older adults, who may be more susceptible to air pollution-induced cardiovascular health effects than younger adults [33], to filtered air containing two levels of ozone (70 ppb and 120 ppb) and to filtered air without ozone. The study was designed to test the hypothesis that short-term exposure to ambient levels of ozone would induce acute cardiovascular responses through the following mechanisms: autonomic imbalance, systemic inflammation, and development of a pro-thrombotic vascular state. Secondary hypotheses were that ozone-induced acute cardiovascular responses would be associated with a) increased systemic oxidative stress and lung effects and b) the GSTM1 null genotype. We report here the results of MOSES with regard to blood biomarkers of systemic inflammation and a prothrombotic state. Secondary outcomes included markers of oxidative stress and endothelial function. Ozone effects on pulmonary and cardiovascular function in this study are reported elsewhere [34–36].

**Materials and methods**

The design for MOSES has been previously described in detail [36]. The study protocol and other study documents are available at [www.healtheffects.org](http://www.healtheffects.org). Briefly, MOSES was a controlled exposure study of the acute cardiovascular effects of ozone inhalation in healthy non-smoking adults (ages 55 to 70 years). The study was conducted in three clinical centers: the University of Rochester Medical Center (URMC), the University of North Carolina (UNC), and the University of California, San Francisco (UCSF); exposures were conducted from 2012 to 2015. The subjects underwent 3 randomized exposure sessions, each consisting of 3 consecutive days. At approximately noon on the first day of each session phlebotomy was performed; the second day involved randomized exposures to clean air (0 ppb), 70 ppb, and 120 ppb ozone for...
3 h while alternately exercising and resting for 15 min, with phlebotomy 4 h after exposure; phlebotomy was performed again on the third day, 22 h after exposure. Exposure sessions were separated by a minimum of 2 weeks. Blood was collected from the antecubital vein of the arm not used for other procedures, into tubes containing sodium citrate. *In situ* platelet and endothelial activation were minimized by a short tourniquet time, minimizing trauma at needle entry, and discarding the first 5 mL of blood. Subjects with difficult venous access were excluded. The subjects, investigators, and study personnel, with the exception of the individual controlling the exposure chambers, were unaware of the nature of the exposures. The total duration of subject participation, from the screening visit to the final visit, typically varied between 3 and 6 months, but could be as long as 12 months. Fig 1 shows the number of subjects at each stage of the study, and Fig 2 shows the timeline for each exposure session.

**Subject recruitment**

Written informed consent was obtained from all subjects at each clinical center. The study was approved by the institutional review board at each center and by the US EPA Human Subjects Research Review Official. A Certificate of Confidentiality was obtained from the US
Department of Health and Human Services. The study was registered with ClinicalTrials.gov, Identifier NCT01487005.

Subjects were recruited through advertisements at the three clinical centers. Inclusion criteria were as follows: nonsmoking males and females of all ethnic backgrounds, ≥55 and ≤70 years of age; normal spirometry (forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC) ≥75% of NHANES predicted values and FEV₁/FVC ≥0.65); ability to complete the training exercise regimen chosen to induce an inspired ventilation rate of 15–17 L body temperature and pressure, saturated (BTPS) /min/m² body surface area (BSA), without exceeding 80% of predicted maximal heart rate; normal baseline 12-lead resting ECG, and absence of significant ST depression while performing the 15-min required level of exercise targeted for the exposure period; ability to avoid a specific list of medications and supplements.

Exclusion criteria were as follows: non-English speaking; reported chronic cardiovascular or respiratory disease, diabetes, or other organ or system dysfunction; active psychiatric disorders that would interfere with the subject’s ability to understand and participate in the study; current drug or alcohol abuse; ever-smokers (smoked tobacco or marijuana during the last five years, or with history of >10 pack-years for tobacco or >1 joint-year for marijuana, or living with a smoker who smokes inside the house); plasma cotinine level >3 ng/mL; body mass index (BMI) >35 and <18; blood pressure >140 systolic or >90 diastolic or on anti-hypertension medications other than diuretics; pregnancy or nursing (breastfeeding); on the following medications: prednisone, statins, beta-blockers, anticoagulants, current systemic estrogen therapy, tamoxifen; and current occupational exposures to high levels of vapors, dust, gases, or fumes.

Subjects were not studied within 6 weeks of a respiratory infection and were asked to abstain from caffeinated and alcoholic beverages starting with lunch on the day before the exposure through the post-exposure day.

Exposure generation and characterization

The exposures took place in ventilated, climate-controlled chambers at each of the clinical centers. The chamber characteristics and specific protocols for generating and measuring ozone were site-specific and are described elsewhere [36].

All three centers generated ozone by silent electric-arc discharge in breathing-quality (USP grade) oxygen from a gas cylinder. The dilution air entering the exposure chamber was purified by passing it through Purafil, charcoal, and HEPA filters. The effluent from the ozone generator was mixed with the filtered air immediately before entering the chamber. The ozone output was controlled by varying the voltage of the generator and adjusting the flow rate. Temperature and relative humidity were targeted at 22°C and 40%, respectively. The concentration of ozone breathed by the subject was monitored continuously during the exposure by calibrated and externally certified analyzers.
Outcomes

The MOSES outcomes were selected based on hypothesized cardiovascular mechanisms of action of ozone. For each potential mechanistic pathway we identified one or more primary outcomes (listed in bold below) and several secondary outcomes, based on either previous evidence in the ozone health effects literature or clinical relevance.

In this paper, we report effects on peripheral blood biomarkers of systemic inflammation, oxidative stress, and endothelial function (CRP, interleukin-6 [IL-6], 8-isoprostane, P-selectin, nitrotyrosine, endothelin-1 [ET-1]), and a prothrombotic state (microparticle-associated tissue factor activity [MP-TFA], von Willebrand factor [vWF], fibrinogen, and flow-cytometric indices of platelet activation, including monocyte-platelet conjugate count, activated platelet [CD62P+] count, platelet-derived microparticle [CD42b+] count, activated platelet-derived microparticle [CD42b+/62P+] count, tissue factor expressing microparticle [CD142+] count, and CD40 ligand-expressing microparticle [CD154+] count).

Assays

Microparticle-associated tissue factor activity. Plasma samples for the MP-TFA assay were analyzed as previously described [37, 38], at the MP-TFA Core Laboratory at UNC. Briefly, microparticles were isolated from plasma by adding 1 mL calcium-free HEPES buffer to each 200 µL sample and pelleting at 20,000 g for 15 min at 4°C. The pellet was washed and resuspended in the same buffer. The MP-TF assay depends on adding calcium in the presence of activated human factor VII (FVIIa) (Enzyme Research Lab). The TF-FVIIa complex plus Ca++ activates added factor X (FX) (Enzyme Research Lab). The resulting FXa was then assayed colorimetrically (absorbance at 405 nm) in the MP pellet suspension along with suitable controls and standards in a 96-well plate with Pefachrome FXa 8595 (Pentapharm #085-27, Aesch, Switzerland) [37]. An essential control, the determination of TF-independent FXa generation, in this system involved first neutralizing TF with anti-human TF antibody (HTF-1) (Becton-Dickinson Biosciences #550252, San Jose, CA). Two plasma samples, in duplicate, were analyzed for each subject time point. Data are reported as the average of the two measurements.

Platelet activation and circulating microparticles. We measured blood platelet activation and circulating microparticles using immunofluorescence and flow cytometry (FC), with modifications of methods previously reported [39]. The FC analyses were conducted at each clinical center within 1 hour of the blood draw, on 18-color LSRII flow cytometers (Becton Dickinson Biosciences, San Jose, CA), using the following laser options: blue 488, 515/20 nm band pass; red 633, 620/20 nm band pass; and green 532, 575/25 nm band pass. Standardized beads were run simultaneously with the subject samples for sizing (SORP-NIST sizing beads, obtained by special order from Becton Dickinson), event counting (AccuCount Beads, ACBP-20-10, obtained by special order from Spherotech, Lake Forest, IL), and fluorescence intensity (Rainbow Beads, RCP-60-5, Spherotech). Platelets and microparticles were characterized both unstimulated and “primed” with thrombin receptor activator peptide (TRAP)-6 (H-8365, Bachem Americas Inc., Torrance, CA), at a concentration (2.34 µM) just below that causing detectable activation using our methods. Marker ligand measurements included both counts of positive events and mean fluorescence intensity of the event population. Data were collected in list mode and sent to the Flow Core at URMC for analysis when each subject’s exposures were completed.

The list mode data collected at each Center were analyzed using FloJo software (TreeStar, Ashland, OR). Platelets and monocyte-platelet conjugates were analyzed using a method adapted from Li et al. [40]. Microparticles were identified using the sizing beads and surface
markers of the cells of origin [41]. Before starting the study, the analysis protocols and procedures were developed and validated using a series of pilot blood samples from healthy volunteers at each study site, with analysis at the Flow Core, to assure consistent results among the study sites. All data were analyzed at the Flow Core by the same individual. A second technician performed duplicate analyses using the same methods on complete data from three subjects, one from each site, to confirm that results were not operator-dependent.

**Commercial laboratory measurements.** CRP, IL-6, 8-isoprostane, nitrotyrosine, fibrinogen, ET-1, and vWF were measured in blood plasma by the AssayGate commercial laboratory (Ijamsville, MD). The specific assays used are described below. The laboratory utilized custom-designed antibody kits that are proprietary. The limit of detection (LOD) of each assay was defined as the value calculated from the standard curve at the point lying 2 standard deviations above the mean background media fluorescence intensity for 10 replicates.

Luminex bead-based multiplex immunoassays were used to measure CRP, fibrinogen, vWF, IL-6, and P-selectin (Luminex® xMAP® technology (Austin, TX). Dilution was performed for samples falling outside the range of the standard curves. Samples were tested in duplicate. Positive controls with known analyte concentrations and negative controls on each bead plate allowed for assay quality assurance. Sandwich enzyme-linked immunosorbent assays (ELISA) were used to measure ET-1 and nitrotyrosine. A competitive ELISA was used to measure 8-isoprostane. A 4-parameter standard curve was prepared relating color intensity to the concentration of the target on each plate. Positive and negative controls on each plate allowed for assay quality assurance.

**Statistical analysis**

Power calculations for selected outcomes were performed prior to study initiation and again during the study. Details of these analyses can be found at https://www.healtheffects.org/system/files/MOSES-Pt1-AddtlMaterials-5.pdf.

Outcomes were calculated by subtracting the pre-exposure value from each post-exposure value. Any of these outcome variables that were not normally distributed, via the Kolmogorov-Smirnov test, were transformed using the natural logarithm (adding 0.001 to 0 values). This resulted in more normal distributions of these outcomes. Outcome variables that were normally distributed were summarized using means with SDs, and those that were skewed, and transformed as described above, were summarized using both means with SDs and medians with inter-quartile ranges. Age was treated as a continuous value and centered by subtracting the mean age for the cohort.

Linear mixed effect models, with a random subject effect and a ‘variance components’ covariance structure, were used to evaluate the impact of exposure to ozone on the pre-specified primary and secondary outcomes. Ozone was treated as a categorical (3-level) variable, with clinical center and time of measurement (also categorical) included in all models. When there was a statistically significant effect of ozone on an outcome, the ozone by time interaction was then assessed to determine whether the ozone effect was consistent across the individual post-exposure times. Since this study involved a large number of comparisons, we pre-specified a limited number of outcomes as primary (three of these primary variables are reported here), and used $\alpha = 0.01$ as the threshold for statistical significance, with $\alpha = 0.05$ as the threshold for marginal significance. Results were then interpreted within the context of coherence among related variables, and plausibility. Significant changes in secondary variables were to be considered hypothesis-generating but not definitive, unless there were changes consistent with effects on the primary outcome variable(s) for that response pathway. In that case, the secondary variable was considered supportive of the findings for the primary variable(s). Analyses
were performed using SAS, Version 9.3 or later (SAS Institute, Cary, NC) and R version 3.2.2 or later (The R Foundation for Statistical Computing).

**Results**

A total of 1,062 individuals responded to the advertisements of the three clinical centers, and 594 of these underwent telephone screening (Fig 1). Eighty-seven subjects completed all three exposures and were included in the analyses; their characteristics are shown in Table 1. Fifty-two (60%) were women and 35 were men. The mean (standard deviation [SD]) age of the subjects was 59.9 (4.5) years. The majority of subjects (88%) identified themselves as white, with African American being the next most common with 5 (6%). Overall, 50 (57%) of the subjects were GSTM1 null, and the prevalence was consistent across the three centers.

**Exposure conditions**

The ozone concentrations in the chambers of all three centers were close to the target values. The mean (SD) temperature was 22.3 (0.7)˚C, compared to the target of 22˚C, and the mean (SD) relative humidity was 41.4 (3.0) %, compared to the target of 40%.

**Effects of ozone on blood biomarkers**

Systemic inflammation, oxidative stress, and endothelial function.

Ozone caused no change in plasma CRP, IL-6, 8-isoprostane, or P-selectin. Descriptive statistics are shown in Table 2; the distribution of values for CRP is skewed (Table 3). Linear

Table 1. Characteristics of MOSES subjects by center.

| Gender | URMC (N = 32) (%) | UNC (N = 29) (%) | UCSF (N = 26) (%) | Overall (N = 87) (%) |
|--------|------------------|------------------|------------------|---------------------|
| Male   | 12 (37.5)        | 9 (31.0)         | 14 (53.8)        | 35 (40.2)           |
| Female | 20 (62.5)        | 20 (69.0)        | 12 (46.2)        | 52 (59.8)           |
| Race   |                  |                  |                  |                     |
| American Indian | 1 (3.1) | 0 (0) | 0 (0) | 1 (1.1) |
| Asian  | 0 (0)            | 0 (0)            | 2 (7.7)          | 2 (2.3)             |
| Black  | 1 (3.1)          | 4 (13.8)         | 0 (0)            | 5 (5.7)             |
| White  | 28 (87.5)        | 25 (86.2)        | 23 (88.5)        | 76 (87.4)           |
| Hawaiian | 0 (0)    | 0 (0)            | 1 (3.8)          | 1 (1.1)             |
| Unknown| 1 (3.1)          | 0 (0)            | 0 (0)            | 1 (1.1)             |

GSTM1

|       | URMC (N = 32) (%) | UNC (N = 29) (%) | UCSF (N = 26) (%) | Overall (N = 87) (%) |
|-------|------------------|------------------|------------------|---------------------|
| Wild type | 15 (46.9) | 13 (44.8) | 9 (34.6) | 37 (42.5) |
| Null  | 17 (53.1)        | 16 (55.2)        | 17 (65.4)        | 50 (57.4)           |
| Age (yrs) | 59.1 ±3.8*      | 60.4 ±5.1        | 60.3 ±4.7        | 59.9 ±4.5           |
| BMI (kg/m²) | 25.0 ±2.4    | 24.8 ±3.7        | 24.8 ±3.6        | 24.9 ±3.2           |
| Systolic BP (mmHg) | 122.4 ±11.4  | 120.4 ±9.7       | 122.2 ±12.8      | 121.7 ±11.2         |
| Diastolic BP (mmHg) | 69.0 ±7.5   | 76.1 ±7.8        | 73.7 ±10.7       | 72.8 ±9.1           |
| Cholesterol Total (mg/dL) | 208.3 ±34.7 | 215.3 ±30.7      | 215.8 ±47.5      | 212.9 ±37.6         |
| LDL Calc (mg/dL) | 118.4 ±30.0 | 119.6 ±29.2      | 123.7 ±41.8      | 120.4 ±33.4         |
| % predicted FEV₁ | 104.0 ±12.8 | 102.4 ±13.9      | 102.6 ±12.9      | 103.0 ±13.1         |

URMC, University of Rochester Medical Center; UNC, University of North Carolina; UCSF, University of California San Francisco; GSTM1, glutathione S-transferase Mu 1 gene; BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein cholesterol; FEV₁, forced expiratory volume in 1 s.

*Mean±SD.

[https://doi.org/10.1371/journal.pone.0222601.t001](https://doi.org/10.1371/journal.pone.0222601.t001)
regression analysis results are shown in Table 4. There were no statistically significant associations of ozone with any of these biomarkers, and no interactions with sex, age, or GSTM1 status (Tables A-X in S1 Appendix). In a sensitivity analysis, there were no significant ozone effects on CRP when subjects with baseline CRP values above the median were excluded.

Table 2. Descriptive statistics for systemic inflammatory, oxidative stress, and endothelial function outcomes.

| Outcome | 0 ppb | 70 ppb | 120 ppb |
|---------|-------|--------|---------|
| CRP (mg/L) | | | |
| Pre Exposure | 85 | 2.72 | 3.56 | 85 | 2.94 | 3.66 | 84 | 3.05 | 4.01 |
| 4 h Post Exposure | 85 | 2.49 | 3.42 | 85 | 2.48 | 3.43 | 84 | 2.71 | 3.67 |
| 22 h Post Exposure | 82 | 2.75 | 3.66 | 85 | 2.81 | 3.83 | 82 | 2.70 | 3.84 |
| IL-6 (pg/mL) | | | |
| Pre Exposure | 85 | 3.25 | 3.14 | 85 | 3.26 | 3.03 | 84 | 3.03 | 2.65 |
| 4 h Post Exposure | 85 | 3.28 | 2.85 | 85 | 2.84 | 2.21 | 84 | 2.83 | 2.34 |
| 22 h Post Exposure | 82 | 3.34 | 2.80 | 85 | 3.31 | 3.33 | 82 | 2.89 | 2.73 |
| 8-Isoprostane (pg/mL) | | | |
| Pre Exposure | 85 | 61.65 | 30.12 | 85 | 61.07 | 31.49 | 84 | 61.99 | 33.72 |
| 4 h Post Exposure | 85 | 57.98 | 27.13 | 85 | 55.38 | 25.11 | 84 | 59.55 | 30.86 |
| 22 h Post Exposure | 82 | 63.00 | 32.74 | 85 | 59.89 | 28.69 | 82 | 60.40 | 26.29 |
| P-selectin (ng/mL) | | | |
| Pre Exposure | 85 | 68.59 | 76.95 | 85 | 69.93 | 69.88 | 84 | 65.43 | 55.57 |
| 4 h Post Exposure | 85 | 63.09 | 48.74 | 85 | 55.62 | 35.02 | 84 | 62.10 | 41.30 |
| 22 h Post Exposure | 82 | 116.71 | 1010.3 | 85 | 77.06 | 1138.5 | 82 | 514.9 | 437.0 |
| Nitrotyrosine (nM) | | | |
| Pre Exposure | 85 | 621.6 | 885.8 | 85 | 641.0 | 1066.7 | 84 | 606.5 | 807.2 |
| 4 h Post Exposure | 85 | 629.3 | 905.2 | 85 | 659.1 | 1169.0 | 84 | 592.9 | 758.6 |
| 22 h Post Exposure | 82 | 678.0 | 1010.3 | 85 | 647.6 | 1138.5 | 82 | 514.9 | 437.0 |
| ET-1 (pg/mL) | | | |
| Pre Exposure | 85 | 1.27 | 0.42 | 85 | 1.26 | 0.35 | 84 | 1.18 | 0.40 |
| 4 h Post Exposure | 85 | 1.24 | 0.43 | 85 | 1.22 | 0.36 | 84 | 1.24 | 0.47 |
| 22 h Post Exposure | 82 | 1.23 | 0.51 | 85 | 1.17 | 0.40 | 82 | 1.20 | 0.44 |
| Fibrinogen (μg/mL) | | | |
| Pre Exposure | 85 | 1649.4 | 2270.0 | 85 | 1790.0 | 2118.4 | 84 | 1319.0 | 1304.7 |
| 4 h Post Exposure | 85 | 1459.2 | 1836.7 | 85 | 1520.8 | 1625.4 | 84 | 1346.0 | 1321.3 |
| 22 h Post Exposure | 82 | 1657.1 | 2069.0 | 85 | 1544.9 | 1795.9 | 82 | 1749.0 | 1864.5 |

CRP, c-reactive protein; IL-6, interleukin-6; ET-1, endothelin-1.
*Primary outcome bolded.

https://doi.org/10.1371/journal.pone.0222601.t002

Table 3. Median and IQR of skewed data for CRP.

| CRP (mg/L) | 0 ppb | 70 ppb | 120 ppb |
|------------|-------|--------|---------|
| Pre Exposure | | | |
| N | Median | IQR | N | Median | IQR | N | Median | IQR |
| 85 | 1.51 | (0.59, 3.43) | 85 | 1.91 | (0.65, 3.75) | 84 | 1.73 | (0.65, 3.17) |
| 4 h Post Exposure | | | |
| 85 | 1.48 | (0.65, 2.97) | 85 | 1.44 | (0.52, 2.87) | 84 | 1.33 | (0.67, 2.88) |
| 22 h Post Exposure | | | |
| 82 | 1.39 | (0.60, 3.60) | 85 | 1.40 | (0.63, 3.27) | 82 | 1.45 | (0.72, 3.61) |

CRP, c-reactive protein.

https://doi.org/10.1371/journal.pone.0222601.t003
Nitrotyrosine decreased after 120 ppb ozone. In linear regression analysis, ozone effects on nitrotyrosine were marginally statistically significant (p = 0.017). As shown in Fig 3, panel B, nitrotyrosine increased 22 hr after 0 ppb ozone exposure but decreased in a concentration-response pattern after 70 and 120 ppb compared to 0 ppb. Nitrotyrosine was unchanged at 4 hr. We found no significant interaction of ozone with sex, age, or GSTM1 status (Tables Y-Ff in S1 Appendix).

ET-1 increased after 120 ppb, but not after 70 ppb ozone. In linear regression analysis, ozone effects on ET-1 were statistically significant (p = 0.008, Table 4). While there was no change in ET-1 after 70 ppb compared to 0 ppb at either 4 h or 22 h after exposure, it increased at both time points after 120 ppb compared to 0 ppb (Fig 3, panel A). We found no statistically significant interactions of ozone with sex, age, or GSTM1 genotype (Tables Gg-Ll in S1 Appendix).

Prothrombotic vascular status.

Ozone exposure did not increase platelet activation. The summary statistics for each primary and secondary marker are shown in Table 5, and the model results are shown in Table 6. There were no significant ozone effects on any of the markers of platelet activation. We found a marginally significant interaction between ozone and age for monocyte-platelet conjugates (p = 0.013, Tables Oo and Pp in S1 Appendix). For every 1-year increase in age, exposure to 70 ppb ozone resulted in a 2.2 lower monocyte-platelet conjugate count (95% CI, -0.7, -3.6), and exposure to 120 ppb ozone resulted in a 1.5 lower monocyte-platelet conjugate count (95% CI, -0.06, -3.0; p = 0.041). There was no significant interaction with sex or GSTM1 (Tables Qq-Tt in S1 Appendix).

Table 4. Main analysis: Ozone effects on systemic inflammatory, oxidative stress, and endothelial function outcomes.

| Outcome | Ozone (ppb) | Difference in estimates | 95% CI | Type III SS | P-value |
|---------|-------------|-------------------------|--------|-------------|---------|
| CRP (mg/L) | 120 | -0.15 | -0.54, 0.23 | 0.655 |
| | 70 | -0.16 | -0.54, 0.23 | |
| | 0 | --- | --- | |
| IL-6 (pg/mL) | 120 | -0.22 | -0.73, 0.29 | 0.567 |
| | 70 | -0.25 | -0.75, 0.26 | |
| | 0 | --- | --- | |
| 8-isoprostane (pg/mL) | 120 | -0.88 | -5.87, 4.10 | 0.749 |
| | 70 | -1.91 | -6.85, 3.04 | |
| | 0 | --- | --- | |
| P-selectin (ng/mL) | 120 | -14.06 | -42.37, 14.26 | 0.235 |
| | 70 | -24.28 | -52.41, 3.85 | |
| | 0 | --- | --- | |
| Nitrotyrosine (nM) | 120 | -41.5 | -70.1, -12.8 | 0.017 |
| | 70 | -14.2 | -42.7, 14.2 | |
| | 0 | --- | --- | |
| ET-1 (pg/mL) | 120 | 0.07 | 0.01, 0.14 | 0.008 |
| | 70 | -0.03 | -0.09, 0.04 | |
| | 0 | --- | --- | |

SS, sum of squares; CRP, c-reactive protein; IL-6, interleukin-6; ET-1, endothelin-1.

*Linear mixed effect models (see Methods).

Primary outcome bolded.

Change from pre- to post-exposure for 120 ppb compared to 0 ppb ozone, and 70 ppb compared to 0 ppb ozone.

https://doi.org/10.1371/journal.pone.0222601.t004
Ozone exposure did not affect circulating microparticles (MP). There were no significant ozone effects on MP. MP expressing CD40L showed a significant ozone-sex interaction ($p < 0.001$, Table Aaaa in S1 Appendix), with decreases in females and increases in males following ozone, relative to air exposure (Fig 4). There were no significant age or GSTM1 interactions for these outcomes (Tables Yyy, Zzz, Cccc, and Dddd in S1 Appendix).

Ozone exposure did not alter plasma concentrations of vWF or fibrinogen. There were no main ozone effects on vWF (secondary outcome). We observed a marginally significant ozone-age interaction ($p = 0.018$, Tables Kkkk and Llll in S1 Appendix). For every 1-year increase in age, exposure to 120 ppb ozone resulted in a decrease of 1382 ng/mL in vWF (95% CI, -252, -2512, $p = 0.017$).

Fibrinogen decreased with 70 ppb ozone (-157 ug/mL) and increased with 120 ppb ozone (317 ug/mL) relative to 0 ppb ozone exposure, but this did not reach statistical significance.
Table 5. Descriptive statistics for prothrombotic vascular outcomes.

| Outcome* | 0 ppb | 70 ppb | 120 ppb |
|----------|-------|--------|---------|
|          | N    | Mean   | SD      | N   | Mean   | SD      | N   | Mean   | SD      |
| Monocyte-platelet conjugate count |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 78 | 50.1   | 47.7    | 73 | 47.4   | 42.0    | 76 | 52.9   | 49.7    |
| 4 h Post Exposure | 78 | 51.2   | 42.6    | 73 | 44.8   | 31.2    | 76 | 51.0   | 42.2    |
| 22 h Post Exposure | 74 | 45.1   | 40.1    | 73 | 42.7   | 27.8    | 74 | 49.7   | 41.9    |
| Activated platelet count |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 82 | 20927.7 | 21222.8 | 80 | 18031.1 | 18312.0 | 82 | 19654.0 | 16465.4 |
| 4 h Post Exposure | 81 | 17532.7 | 12192.9 | 79 | 16117.8 | 14006.0 | 82 | 16152.5 | 13679.8 |
| 22 h Post Exposure | 78 | 20587.0 | 37302.4 | 79 | 15922.9 | 14867.4 | 80 | 16487.2 | 13555.2 |
| MP-TFA (pg/mL) |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 84 | 0.149  | 0.170   | 84 | 0.130  | 0.178   | 86 | 0.154  | 0.201   |
| 4 h Post Exposure | 84 | 0.147  | 0.192   | 84 | 0.136  | 0.154   | 86 | 0.177  | 0.199   |
| 22 h Post Exposure | 80 | 0.143  | 0.150   | 84 | 0.121  | 0.141   | 84 | 0.152  | 0.159   |
| Platelet MP count |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 81 | 5205.2 | 4028.4  | 80 | 5101.1 | 2940.9  | 81 | 5397.6 | 4112.5  |
| 4 h Post Exposure | 80 | 4677.8 | 3207.6  | 79 | 5025.9 | 3619.3  | 81 | 5038.3 | 3314.0  |
| 22 h Post Exposure | 77 | 4236.3 | 2237.8  | 79 | 4557.0 | 2554.8  | 79 | 4948.2 | 3251.6  |
| Activated platelet MP count |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 81 | 832.3  | 1076.6  | 80 | 723.0  | 752.1   | 81 | 763.0  | 561.3   |
| 4 h Post Exposure | 80 | 686.8  | 620.1   | 79 | 706.8  | 679.5   | 81 | 685.6  | 448.8   |
| 22 h Post Exposure | 77 | 590.8  | 415.8   | 79 | 603.3  | 427.4   | 79 | 668.1  | 422.4   |
| CD142+MP count |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 80 | 25033.5 | 40847.4 | 80 | 22555.8 | 32787.7 | 80 | 29834.9 | 56386.7 |
| 4 h Post Exposure | 79 | 22881.8 | 50998.0 | 79 | 15907.7 | 20139.5 | 80 | 20071.2 | 31808.0 |
| 22 h Post Exposure | 76 | 15082.1 | 23611.4 | 79 | 17851.5 | 31657.5 | 78 | 19492.0 | 28543.7 |
| CD40 Ligand+ MP count |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 80 | 3283.4 | 57668.5 | 80 | 32007.5 | 48664.5 | 80 | 37502.8 | 66018.2 |
| 4 h Post Exposure | 79 | 30629.2 | 60380.1 | 79 | 23561.1 | 31098.3 | 80 | 24390.1 | 31387.4 |
| 22 h Post Exposure | 76 | 21909.8 | 30699.2 | 79 | 20977.3 | 23635.2 | 78 | 26681.8 | 36682.2 |
| Platelet count (1000/uL) |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 84 | 236.8  | 51.8    | 85 | 237.2  | 59.3    | 85 | 233.9  | 51.3    |
| 4 h Post Exposure | 83 | 231.4  | 48.5    | 85 | 230.7  | 61.2    | 84 | 228.8  | 52.3    |
| 22 h Post Exposure | 80 | 230.3  | 54.9    | 85 | 226.7  | 61.5    | 81 | 225.9  | 52.7    |
| vWF (ng/mL) |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 85 | 23774.0 | 24127.0 | 85 | 22101.0 | 26088.1 | 84 | 22450.3 | 21076.3 |
| 4 h Post Exposure | 85 | 23606.5 | 26519.2 | 85 | 23198.3 | 26646.7 | 84 | 21234.9 | 19271.9 |
| 22 h Post Exposure | 82 | 24703.3 | 25631.4 | 85 | 22359.2 | 36850.5 | 82 | 21645.4 | 24122.8 |
| Fibrinogen (μg/mL) |       |        |         |     |        |         |     |        |         |
| Pre Exposure | 85 | 1649.4 | 2270.0  | 85 | 1790.0 | 2118.4  | 84 | 1319.0 | 1304.7  |
| 4 h Post Exposure | 85 | 1459.2 | 1836.7  | 85 | 1520.8 | 1625.4  | 84 | 1346.0 | 1321.3  |
| 22 h Post Exposure | 82 | 1657.1 | 2069.0  | 85 | 1544.9 | 1795.9  | 82 | 1749.0 | 1864.5  |

MP-TFA, microparticle-associated tissue factor activity; MP, microparticles; vWF, von Willebrand factor.

*Primary outcomes are bolded.

https://doi.org/10.1371/journal.pone.0222601.t005
There were no significant age, sex or GSTM1 interactions (Tables Qqqq-Vvvv in S1 Appendix). Fibrinogen levels were 575 μg/mL higher (CI: 6, 1144) in GSTM1 null subjects, independent of ozone exposure.

Discussion

In this study, we tested the hypothesis that short-term exposure of healthy older adults to near-ambient levels of ozone would induce systemic inflammation leading to endothelial dysfunction and development of a pro-thrombotic vascular state. We chose to study older subjects, postulating that ozone effects would be more likely to lead to acute cardiovascular effects in older than younger subjects. We also postulated that the GSTM1 null genotype would modify responses to ozone exposure. In this panel of 55–70 year-old healthy subjects, we found little

| Outcome                       | Ozone (ppb) | Estimates | 95% CI       | Type III SS P-value |
|-------------------------------|-------------|-----------|--------------|---------------------|
| Monocyte-platelet conjugates (count) | 120         | -0.2      | -6.8, 6.4    | 0.873               |
|                               | 70          | -1.6      | -8.3, 5.0    |                     |
|                               | 0           | -         | ---          |                     |
| Activated platelets (count)   | 120         | -1437.3   | -5686.6, 2812.0 | 0.781              |
|                               | 70          | -314.3    | -4591.6, 3962.1 |                     |
|                               | 0           | -         | ---          |                     |
| MP-TFA (pg/mL)                | 120         | 0.009     | -0.030, 0.048 | 0.772               |
|                               | 70          | -0.005    | -0.044, 0.034 |                     |
|                               | 0           | -         | ---          |                     |
| Platelet MP (count)           | 120         | 213.7     | -382.6, 810.0 | 0.524               |
|                               | 70          | 341.7     | -256.9, 940.3 |                     |
|                               | 0           | -         | ---          |                     |
| Activated platelet MP (count) | 120         | 75.3      | -92.6, 243.2 | 0.514               |
|                               | 70          | 92.9      | -75.7, 261.5 |                     |
|                               | 0           | -         | ---          |                     |
| CD142+ MP (count)             | 120         | -4444.2   | -12932.0, 4043.6 | 0.551             |
|                               | 70          | -927.1    | -9418.6, 7564.3 |                     |
|                               | 0           | -         | ---          |                     |
| CD40L MP (count)              | 120         | -6516.9   | -15307.0, 2273.6 | 0.306             |
|                               | 70          | -5186.7   | -13984.0, 3610.7 |                     |
|                               | 0           | -         | ---          |                     |
| Platelet count (1000/uL)      | 120         | 1.3       | (-1.7, 4.4)  | 0.190               |
|                               | 70          | -1.5      | (-4.5, 1.6)  |                     |
|                               | 0           | -         | ---          |                     |
| vWF (ng/mL)                   | 120         | -1527.6   | -6719.4, 3664.2 | 0.765             |
|                               | 70          | 246.3     | -4913.4, 5406.0 |                     |
|                               | 0           | -         | ---          |                     |
| Fibrinogen (ug/mL)            | 120         | 317.3     | -67.8, 702.4  | 0.048               |
|                               | 70          | -157.3    | -539.9, 225.4 |                     |
|                               | 0           | -         | ---          |                     |

MP-TFA, microparticle-associated tissue factor activity; MP, microparticles; vWF, von Willebrand factor.

*Primary outcomes are bolded.

Change from pre- to post-exposure for each ozone concentration, compared to 0 ppb.

https://doi.org/10.1371/journal.pone.0222601.t006

(p = 0.048). There were no significant age, sex or GSTM1 interactions (Tables Qqqq-Vvvv in S1 Appendix). Fibrinogen levels were 575 μg/mL higher (CI: 6, 1144) in GSTM1 null subjects, independent of ozone exposure.
evidence of effects of controlled exposure to low levels of ozone on a battery of peripheral venous blood biomarkers of systemic inflammation, oxidative stress, endothelial function, and pro-thrombotic state.

Systemic inflammation, oxidative stress, and endothelial function

Chronic inflammation has been implicated in the pathogenesis of atherosclerosis and CRP is the inflammatory biomarker that has been most consistently associated with cardiovascular disease risk [42]. It is an acute-phase protein that is produced in the liver in response to pro-inflammatory cytokines, in particular IL-6. It is considered a non-specific marker of inflammation and the mechanism by which CRP contributes to cardiovascular disease risk is unknown.

Several controlled human exposure studies have documented that inhaled ozone at high ambient concentrations can cause airway inflammation characterized by increased neutrophils and pro-inflammatory cytokines in bronchoalveolar lavage or sputum [4, 43]. It is reasonable to suspect that ozone-induced lung inflammation might "spill over" into the systemic circulation, and some data exist to support this concept. A study of pre-exposure levels of serum IL-6 among 45 participants in controlled human exposure studies, in relation to ambient pollutant concentrations in Toronto, reported a positive association between IL-6 and ozone, with the strongest association using a 4-day moving average (~30 ppb) in the summer [44]. Serum CRP increased in two recent controlled human exposure studies in which the ozone concentration ranged from 100–300 ppb [27, 28]. CRP increased after exposure to 200 ppb but not 100 ppb in the Arjomandi et al. study, and only relatively late (18–24 hours) after exposure in both studies. The mean of the pre-exposure levels of CRP in the MOSES study was higher than that reported in those two studies (2.6 mg/L versus 0.6–0.7 mg/L), likely reflecting the older age of our subjects. A sensitivity analysis, using only subjects whose pre-exposure values were below the median of 1.5 mg/L, did not change the results.

Oxidative stress represents an imbalance between the formation of reactive oxygen species in a tissue and that tissue’s antioxidant capacity to detoxify the reactive intermediates. Oxidative stress has been implicated in the pathogenesis of atherosclerosis and has been suggested as a risk factor for adverse cardiovascular outcomes [45]. Ozone is a highly reactive oxidant gas...
that can increase oxidative stress in the lung. There are both epidemiological and controlled human exposure data to support increased systemic oxidative stress after ozone exposure [46, 47]. 8-isoprostane, a product of lipid peroxidation, has been used as a marker of oxidative stress in previous studies [48, 49].

Based on these data, we hypothesized that ozone exposure would increase serum levels of IL-6, CRP and 8-isoprostane. However, our results showed no evidence of an effect of ozone at either 70 or 120 ppb on these biomarkers of inflammation and oxidative stress. A potential reason for the difference between MOSES results and those of previous controlled human exposure studies is that MOSES subjects were 55–70 years of age while previous studies recruited young adults. Another potential reason is the higher inhaled dose of ozone to which the young adult subjects were exposed in previous studies. It is also possible that our earliest plasma 8-isoprostane measurement, 4 h post-exposure, missed an earlier, transient effect of ozone exposure. However, this time point was selected based on the significant increase reported [46] after exposure of young adults to 200 ppb over 4 h with intermittent exercise. Nonetheless, given that we measured only one biomarker of lipid peroxidation (8-isoprostane), in plasma only (measurement in urine or exhaled breath condensate are alternative approaches), we cannot exclude the possibility of ozone-induced systemic oxidative stress in exercising older subjects.

Nitrotyrosine is a product of tyrosine nitration mediated by reactive nitrogen species such as peroxynitrite anion and NO. Oxidative stress increases the production of superoxide anion and NO, forming peroxynitrite, a highly reactive free radical oxidant capable of oxidizing lipoproteins and nitrating protein tyrosine residues. Nitrotyrosine is easier to measure than peroxynitrite and is used as a marker of NO-dependent, reactive nitrogen species-induced nitrative stress. To our knowledge, MOSES is the first controlled human exposure study of ozone to measure plasma nitrotyrosine. In a mouse model, increased nitrotyrosine residues in the lung after ozone exposure were shown to be an inducible NO synthase (NOSII)-dependent response [50]. We hypothesized that ozone would increase nitrotyrosine; however its concentration surprisingly decreased with increasing ozone concentrations, with marginal statistical significance. As shown in Fig 3B, nitrotyrosine decreased slightly 4 hr after 120 ppb ozone, and decreased relative to 0 ppb with increasing ozone concentrations 22 hr after exposure. However, the only change in which the 95% CI did not include 0 was the increase 22 hr after exposure to 0 ppb ozone. It is possible this increase was spurious, and the relative decreases after 70 and 120 ppb represent regression to the mean. Taken together with the marginal significance and direction of change opposite of that hypothesized, we cannot conclude that there were significant effects of ozone exposure on nitrotyrosine. However, it is possible that reduction in nitrotyrosine levels could be caused by ozone-induced upregulation of antioxidant systems and pathways, quenching reactive nitrative stress.

Endothelin-1 (ET-1) is a potent vasoconstrictor peptide originally isolated from endothelial cells that is now known to be produced by multiple cell types when stimulated, and has been linked to air pollution exposure [51–53]. To our knowledge, ET-1 has not been previously evaluated as an outcome in a controlled human exposure study of ozone. Based on previous reports of the biological effects induced by ET-1 including vasoconstriction, pro-inflammatory responses, mitogenesis, cell proliferation, stimulation of free radical formation, and platelet activation [54], we hypothesized that ozone exposure would increase ET-1. This was confirmed, with a significant overall ozone effect on ET-1 (p = 0.008). While we found no change in ET-1 after 70 ppb at either 4 or 22 h after exposure, we did observe a marginally statistically significant increase after 120 ppb (p = 0.028). Endothelin-1 has important interactions with NO and is involved in the development of endothelial dysfunction. Increased production of ET-1 and its receptors may contribute to the pathogenesis of atherosclerosis [55]. However, as reported elsewhere [35], there was no effect of ozone exposure on blood pressure or forearm
flow-mediated dilatation in this study, so the significance of the increase in ET-1 is uncertain. It is possible that the vasoconstrictive effect of increased ET-1 was countered by increases in vasodilators that were not measured, such as NO or prostanoids.

**Prothrombotic vascular status**

Increased propensity for vascular thrombosis has been posited as one of the pathways by which exposure to air pollution leads to adverse cardiovascular events. We found no convincing evidence for ozone effects on platelet activation, circulating MP, or MP-TFA. We did find a significant ozone-sex interaction for CD40L+ MP, which decreased in females and increased in males following ozone, compared with air exposure, suggesting this response to ozone exposure may differ by sex. However, none of the other thrombosis markers supported an ozone effect or sex interaction, so we conclude there is no effect on prothrombotic vascular status at these ozone exposure levels in this population.

A few other controlled human exposure studies have examined ozone effects on markers of coagulation or thrombosis, with variable results. Frampton et al. [29] exposed younger, healthy subjects to 0, 100, and 200 ppb ozone for 3 h, with intermittent exercise. There were no significant effects on platelets or circulating microparticles 4 h after exposure, using methods similar to those in the present study. Devlin et al. [28] exposed healthy subjects to 0 and 300 ppb for 2 h with intermittent exercise. They found no effects on plasma levels of vWF or D-dimer. Plasminogen levels increased 24 h after air exposure but decreased after ozone exposure. They also reported a statistically significant increase in tissue plasminogen activator (tPA) and a significant reduction in plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tPA, 24 h after ozone exposure, relative to air. These findings indicate possible activation of fibrinolysis following ozone exposure, rather than the hypothesized prothrombotic effect.

Arjomandi et al. [27] found no effects of exposure to 100 and 200 ppb ozone on fibrinogen, PAI-1, prothrombin time, partial thromboplastin time, or platelet count. Similarly, Barath et al. [56] found no effects of 300 ppb ozone for 75 min, with intermittent exercise, on tPA or PAI-1 following brachial arterial infusion of bradykinin, 2 and 6 h after exposure to ozone.

A recent controlled human exposure study examined the effect of varying temperature on the effects of ozone exposure [57]. Healthy volunteers were exposed to 0 and 300 ppb ozone for 2 h with intermittent exercise, at two different ambient temperatures. At 22°C, PAI-1 decreased 52%, plasminogen decreased 12%, and D-dimer increased 18%. In contrast, at 32.5°C, PAI-1 increased 45% and plasminogen increased 28%. D-dimer decreased 12.5%. This suggested that the fibrinolytic pathway is impaired following ozone exposure at the lower temperature and activated at the higher temperature.

A few panel studies have examined the effects of ozone exposure on propensity for thrombosis, but the findings are also mixed. Strak et al. [58] obtained blood from young healthy volunteers at five different locations with varying pollutant concentrations. Intrinsic thrombin generation was associated with increased exposures to nitrogen dioxide, nitrates, and sulfates, but not to ozone. In 76 young, healthy subjects in Taiwan, increased ozone exposure was associated with increased fibrinogen and PAI-1, which held up in two-pollutant models [47]. Liao et al. [59] examined data from the ARIC study that included 10,208 middle-aged people, and found ozone exposure was associated with increases in fibrinogen and vWF levels, with greater effects in people with diabetes and cardiovascular disease.

A weight-of-evidence review [60] described evidence from controlled human exposure studies for small increases in markers of inflammation and oxidative stress in response to ozone exposure, but found no consistent effects on blood coagulation in either clinical or epidemiological studies.
Strengths and limitations

This multi-center study has a number of strengths. It is one of the largest controlled human exposure studies of ozone to be conducted to date, providing greater statistical power than previous studies. The study was designed to comprehensively evaluate the mechanistic pathways by which air pollutants may contribute to acute cardiovascular toxicity.

The lack of exposure to a higher inhaled dose of ozone limits comparability to the previous controlled exposure studies described above. We cannot therefore generalize the absence of blood biomarker effects to populations exposed to higher concentrations. Also, since we studied acute responses to short-term ozone exposures, we cannot exclude the possibility of effects of chronic or repeated exposures, or effects delayed longer than 22 h after exposure.

The chamber ozone exposure levels of 120 ppb and 70 ppb used in MOSES were only slightly higher than peak ambient ozone levels occurring at the study centers on some days during the study periods. Thus, it is possible that ambient ozone and other pollutant exposures experienced by the study subjects before and during the study may have independently impacted the study biomarkers, and/or modified, blunted, or lessened any biomarker responses to the controlled ozone exposures. These questions are being examined and will be published separately.

By design, we restricted the participants to older, healthy subjects, who were physically fit enough to complete the exercise regimen, and the findings may not be representative of people in other age groups. People with pre-existing cardiovascular disease may differ in their responses to ozone exposure. The choice to study older subjects was based on the hypothesis that these individuals would be at increased risk for acute cardiovascular effects of ozone, but younger individuals are known to be more responsive to the effects of ozone on lung function, and could also be more responsive to cardiovascular effects.

Subject to the same limitations, other data from the MOSES study also failed to reveal significant acute effects on cardiovascular function [35], although there were significant acute changes in respiratory system parameters [34].

Summary and conclusions

In this multicenter clinical study of older healthy subjects, ozone exposure caused no effects on systemic inflammation. Blood levels of nitrotyrosine decreased with ozone exposure with marginal statistical significance, the opposite of our hypothesis. Blood levels of the potent vasoconstrictor, ET-1, increased with ozone exposure. The results of our study do not support acute effects of low-level ozone exposure in healthy older subjects on systemic inflammation, oxidative stress, or a pro-thrombotic state. We cannot exclude the possibility of effects with higher ozone exposure concentrations or more prolonged exposure, or the possibility that subjects with underlying vascular disease, such as hypertension or diabetes, would show effects under these conditions.

Supporting information

S1 Appendix. Model results for interactions of exposure by age, sex, and GSTM1 status. (DOCX)

S1 Checklist. CONSORT 2010 checklist of information to include when reporting a randomised trial. (DOC)

S2 Checklist. CONSORT checklist notes. (DOCX)
Acknowledgments

We thank Patty Arsenault, Anne Stoddard, Hofer Wong, Martha Almond, Erika Little, David Chalupa, Claire Mills, Heather Wells, Melissa Caughey, Patty Severski, and Pamela Vargo for all their work in coordinating and conducting all aspects of the trial. We also recognize the contribution of Katelyn Nelson, Nancy Gee, Christiana Toomey, and Ashley Wilkinson for their work in data management and analysis. Finally, we would like to thank Mark Utell and Howard Rockette, who provided advice during the development of the protocol and during the course of the study.

Author Contributions

Conceptualization: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Maria G. Costantini, Milan J. Hazucha, David Q. Rich, Mark W. Frampton.

Data curation: Maria G. Costantini, Nicholas Dagincourt, Danielle Hollenbeck-Pringle, David Q. Rich, Paul Stark.

Formal analysis: Nicholas Dagincourt, Danielle Hollenbeck-Pringle, David Q. Rich, Paul Stark.

Funding acquisition: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Maria G. Costantini, Milan J. Hazucha, David Q. Rich, Mark W. Frampton.

Investigation: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Milan J. Hazucha, David Q. Rich, Mark W. Frampton.

Methodology: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Maria G. Costantini, Nicholas Dagincourt, Milan J. Hazucha, Danielle Hollenbeck-Pringle, David Q. Rich, Paul Stark, Mark W. Frampton.

Project administration: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Maria G. Costantini, Milan J. Hazucha, David Q. Rich, Mark W. Frampton.

Resources: John R. Balmes, Philip A. Bromberg, Maria G. Costantini, Milan J. Hazucha, David Q. Rich, Mark W. Frampton.

Software: Nicholas Dagincourt, Danielle Hollenbeck-Pringle, Paul Stark.

Supervision: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Maria G. Costantini, Milan J. Hazucha, David Q. Rich, Mark W. Frampton.

Validation: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Maria G. Costantini, Nicholas Dagincourt, Milan J. Hazucha, Danielle Hollenbeck-Pringle, David Q. Rich, Paul Stark, Mark W. Frampton.

Writing – original draft: John R. Balmes.

Writing – review & editing: John R. Balmes, Mehrdad Arjomandi, Philip A. Bromberg, Maria G. Costantini, Nicholas Dagincourt, Milan J. Hazucha, Danielle Hollenbeck-Pringle, David Q. Rich, Paul Stark, Mark W. Frampton.

References

1. Sun Q, Hong X, Wold LE. Cardiovascular effects of ambient particulate air pollution exposure. Circulation. 2010; 121(25): 2755–2765. https://doi.org/10.1161/CIRCULATIONAHA.109.893461 PMID: 20585020
2. Schelegle ES, Morales CA, Walby WF, Marion S, Allen RP. 6.6-hour inhalation of ozone concentrations from 60 to 87 parts per billion in healthy humans. Am J Respir Crit Care Med. 2009; 180(3): 265–272. https://doi.org/10.1164/rccm.200809-1484OC PMID: 19447899

3. Adams WC. Comparison of chamber 6.6-h exposures to 0.04–0.08 PPM ozone via square-wave and triangular profiles on pulmonary responses. Inhal Toxicol. 2006; 18(2): 127–136. https://doi.org/10.1080/08958370500306107 PMID: 16393927

4. Kim CS, Alexis NE, Rappold AG, Kehrl H, Hazucha MJ, Lay JC, et al. Lung function and inflammatory responses in healthy young adults exposed to 0.06 ppm ozone for 6.6 hours. Am J Resp Crit Care Med. 2011; 183: 1215–1221. https://doi.org/10.1164/rccm.201011-1813OC PMID: 21216881

5. Bell ML, McDermott A, Zeger SL, Samet JM, Dominici F. Ozone and short-term mortality in 95 US urban communities, 1987–2000. JAMA. 2004; 292(19): 2372–2378. https://doi.org/10.1001/jama.292.19.2372 PMID: 15547165

6. Bravo MA, Son J, de Freitas CU, Gouveia N, Bell ML. Air pollution and mortality in Sao Paulo, Brazil: Effects of multiple pollutants and analysis of susceptible populations. J Expo Sci Environ Epidemiol. 2016; 26(2): 150–161. https://doi.org/10.1038/jes.2014.90 PMID: 25586330

7. Ballester F, Rodríguez P, Iniguez C, Saez M, Daponte A, Galan I, et al. Air pollution and cardiovascular admissions association in Spain: results within the EMECAS project. J Epidemiol Community Health. 2006; 60: 328–336. https://doi.org/10.1136/jech.2005.037978 PMID: 16537554

8. Chan CC, Chuang KJ, Chien LC, Ha EH, Park H. Air pollution and hospital admissions for cerebrovascular diseases in Taipei, Taiwan. Eur Heart J. 2006; 27: 1238–1244. https://doi.org/10.1093/eurheartj/ehi835 PMID: 15637545

9. Chang CC, Tsai SS, Ho SC, Yang CH. Air pollution and hospital admissions for cardiovascular disease in Taipei, Taiwan. Environ Res. 2005; 98: 114–119. https://doi.org/10.1016/j.envres.2004.07.005 PMID: 15721891

10. Halonen JI, Lanki T, Tiittanen P, Niemi JV, Loh M, Pekkanen J. Ozone and cause-specific cardiorespiratory morbidity and mortality. J Epidemiol Community Health. 2010; 64(9): 814–820. https://doi.org/10.1136/jech.2009.087106 PMID: 19854743

11. Lee JT, Kim H, Cho YS, Hong YC, Ha EH, Park H. Air pollution and hospital admissions for ischemic heart diseases among individuals 64+ years of age residing in Seoul, Korea. Arch Environ Health. 2003; 58(10): 617–623. https://doi.org/10.3200/AEOH.58.10.617-623 PMID: 15652635

12. Szyzkowicz M. Ambient air pollution and emergency department visits for ischemic stroke in Edmonton, Canada. Int J Occup Med Environ Health. 2008; 21(14): 295–300.

13. Rodopoulou S, Chalbot MC, Samoli E, Dubois DW, San Filippo BD, Kavouras IG. Air pollution and hospital emergency room and admissions for cardiovascular and respiratory diseases in Dona Ana County, New Mexico. Environ Res. 2014; 129: 39–46. https://doi.org/10.1016/j.envres.2013.12.006 PMID: 24529001

14. Barnett AG, Williams GM, Schwartz J, Best TL, Neller AH, Petroeschevsky AL, et al. The effects of air pollution on hospitalizations for cardiovascular disease in elderly people in Australian and New Zealand cities. Environ Health Perspect. 2006; 114(7): 1018–1023. https://doi.org/10.1289/ehp.8674 PMID: 16835053

15. Corea F, Silvestrelli G, Baccarelli A, Giua A, Previdi P, Siliprandi G, et al. Airborne pollutants and lacunar stroke: a case cross-over analysis on stroke unit admissions. Neuroul Int. 2012; 4(2): e11. https://doi.org/10.1136/neurintsurg.2012.054218 PMID: 23139849

16. Franck U, Leitte AM, Suppan P. Multiple exposures to airborne pollutants and hospital admissions due to diseases of the circulatory system in Santiago de Chile. Sci Total Environ. 2014; 468–469: 746–756. https://doi.org/10.1016/j.scitotenv.2013.08.088 PMID: 24064344

17. Fung KY, Luginaah I, Gorey KM, Webster G. Air pollution and daily hospital admissions for cardiovascular diseases in Windsor, Ontario. Can J Public Health. 2005; 96(1): 29–33. PMID: 15682690

18. Goldberg MS, Giannetti N, Burnett RT, Mayo NE, Valois MF, Brophy JM. A panel study in congestive heart failure to estimate the short-term effects from personal factors and environmental conditions on oxygen saturation and pulse rate. Occup Environ Med. 2008; 65(10): 659–666. https://doi.org/10.1136/oem.2007.034834 PMID: 18801926

19. Symons JM, Wang L, Guallar E, Howell E, Dominici F, Schwab M, et al. A case-crossover study of fine particulate matter air pollution and onset of congestive heart failure symptom exacerbation leading to hospitalization. Am J Epidemiol. 2006; 164(5): 421–433. https://doi.org/10.1093/aje/kwj206 PMID: 16793862

20. Tolbert PE, Klein M, Peel JL, Sarnat SE, Sarnat JA. Multipollutant modeling issues in a study of ambient air quality and emergency department visits in Atlanta. J Expo Anal Environ Epidemiol. 2007; 17: S29–S35.
21. Zanobetti A, Schwartz J. Air pollution and emergency admissions in Boston, MA. J Epidemiol Community Health. 2006; 60: 890–895. https://doi.org/10.1136/jech.2005.039834 PMID: 16973538

22. Sarnat SE, Winquist A, Schauer JJ, Turner Jr, Sarnat JA. Fine particulate matter components and emergency department visits for cardiovascular and respiratory diseases in the St. Louis, Missouri-Illinois, metropolitan area. Environ Health Perspect. 2015; 123(5): 437–444. https://doi.org/10.1289/ehp.1307776 PMID: 25575028

23. Shah ASV, Lee KK, McAllister DA, Hunter A, Nair H, Whiteley W, et al. Short term exposure to air pollution and stroke: systematic review and meta-analysis. BMJ. 2015; 350: h1295. https://doi.org/10.1136/bmj.h1295 PMID: 25810496

24. Mustafic H, Jabre P, Caussin C, Murad M, Escolano S, Tafflet M, et al. Main air pollutants and myocardial infarction: a systematic review and meta-analysis. JAMA. 2012; 307(7): 713–721. https://doi.org/10.1001/jama.2012.126 PMID: 22337682

25. Shah ASV, Langrish JP, Nair H, McAllister DA, Hunter AL, Donaldson K, et al. Global association of air pollution and heart failure: a systematic review and meta-analysis. The Lancet. 2013; 382(9897): 1039–1048.

26. U.S. EPA. Integrated Science Assessment for ozone and related photochemical oxidants. Research Triangle Park (NC): U.S. Environmental Protection Agency; 2013, Feb. EPA 600/R-10-076F.

27. Arjomandi M, Wong H, Donde A, Frelinger J, Dalton S, Ching W, et al. Exposure to medium and high ambient levels of ozone causes adverse systemic inflammatory and cardiac autonomic effects. Am J Physiol Heart Circ Physiol. 2015; 308(12): H1499–H1509. https://doi.org/10.1152/ajpheart.00849.2014 PMID: 25862833

28. Devlin RB, Duncan KE, Jardim M, Schmitt MT, Rappold AG, Diaz-Sanchez D. Controlled exposure of healthy young volunteers to ozone causes cardiovascular effects. Circulation. 2012; 126(1): 104–111. https://doi.org/10.1161/CIRCULATIONAHA.112.094359 PMID: 22732313

29. Frampton M, Pietropaoli A, Dentler M, Chalupa D, Little E, Stewart J, et al. Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1. Inhal Toxicol. 2015; 27: 113–119. https://doi.org/10.3109/08958378.2014.996272 PMID: 25600221

30. Wu W, Peden D, McConnell R, Fruin S, Diaz-Sanchez D. Glutathione-S-transferase M1 regulation of diesel exhaust particle-induced pro-inflammatory mediator expression in normal human bronchial epithelial cells. Particle and Fibre Toxicology. 2012; 9(1): 31. https://doi.org/10.1186/1743-8977-9-31 PMID: 22867088

31. Alexis NE, Zhou H, Lay JC, Harris B, Hernandez ML, Lu T-S, et al. The glutathione-S-transferase Mu 1 null genotype modulates ozone-induced airway inflammation in human subjects. J Allergy Clin Immunol. 2009; 124(6): 1222–1228. https://doi.org/10.1016/j.jaci.2009.07.036 PMID: 19796798

32. Alexis NE, Lay JC, Zhou H, Kim CS, Hernandez ML, Kehrl H, et al. The glutathione-S-transferase mu 1 (GSTM1) null genotype and increased neutrophil response to low-level ozone (0.06 ppm). J Allergy Clin Immunol. 2013; 131(2): 610–612. https://doi.org/10.1016/j.jaci.2012.07.005 PMID: 22921799

33. Shumake KL, Sacks JD, Lee JS, Johns DO. Susceptibility of older adults to health effects induced by ambient air pollutants regulated by the European Union and the United States. Aging Clin Exp Res. 2013; 25(1): 3–8. https://doi.org/10.1016/s0955-8179(12)70007-6 PMID: 23740627

34. Arjomandi M, Balsera A, Frampton MW, Bromberg P, Stark P, Alexis NE, et al. Respiratory Responses to Ozone Exposure: The Multicenter Ozone Study in Older Subjects (MOSES). Front. Med. 2018; 197: 1319–1327. https://doi.org/10.3389/fmed.2018.00177 PMID: 29322135

35. Rich D, Balsera A, Frampton M, Zareba W, Stark P, Arjomandi M, et al. Cardiovascular and ozone exposure: The Multicenter Ozone Study in Older Subjects (MOSES). Environ Int. 2018; 119: 193–202. https://doi.org/10.1016/j.envint.2018.06.014 PMID: 29980042

36. Frampton M, Balsera A, Bromberg P, Stark P, Arjomandi M, Hazucha M, et al. Multicenter Ozone Study in Older Subjects: Part 1. Effects of exposure to low concentrations of ozone on respiratory and cardiovascular outcomes. Boston (MA): Health Effects Institute; 2017. Research Report No. 192, Pt. 1.

37. Wang JC, Kobie JJ, Zhang L, Cochran M, Mosmann TR, Ritchlin CT, et al. An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. J Immunol Methods. 2009; 341(1–2): 106–116. https://doi.org/10.1016/j.jim.2008.11.002 PMID: 19049809

38. Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008; 6(11): 1983–1985. https://doi.org/10.1111/j.1538-7836.2008.03156.x PMID: 18795992

39. Stewart JC, Chalupa DC, Devlin RB, Frasier LM, Huang L-S, Little EL, et al. Vascular effects of ultrafine particles in persons with type 2 diabetes. Environ Health Perspect. 2010; 118: 1692–1698. https://doi.org/10.1289/ehp.1002237 PMID: 20822968
Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(7): 483–495. https://doi.org/10.7326/0003-4819-151-7-200910060-00009 PMID: 19805771

Devlin RB, McDonnell WF, Mann R, Becker S, House DE, Schreinemachers D, et al. Exposure of humans to ambient levels of ozone for 6.6 hours causes cellular and biochemical changes in the lung. Am J Respir Cell Mol Biol. 1991; 4: 72–81. https://doi.org/10.1165/ajrcmb/4.1.72 PMID: 18087591

Jimenez JJ, Wenche J, Mauro LM, Horstman LL, Bidot CJ, Ahn YS. Endothelial microparticles (DMP) as vasodilation markers. Adv Clin Chem. 2005; 39: 131–153. PMID: 16013670

Li N, Goodall AH, Hjemdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry. 1999; 35(2): 154–161. PMID: 10554171

Thompson AMS, Zanobetti A, Silverman F, Schwartz J, Coull B, Urch B, et al. Baseline repeated measures from controlled human exposure studies: Associations between ambient air pollution exposure and the systemic inflammatory biomarkers IL-6 and fibrinogen. Environ Health Perspect. 2010; 118: 120–124. https://doi.org/10.1289/ehp.0900550 PMID: 20056584

Schnabel R, Blankenberg S. Oxidative stress in cardiovascular disease: successful translation from bench to bedside? Circulation. 2007; 116(12): 1338–1340. https://doi.org/10.1161/CIRCULATIONAHA.107.728394 PMID: 17859798

Chen C, Arjomand M, Balmes J, Tager I, Holland N. Effects of chronic and acute ozone exposure on lipid peroxidation and antioxidant capacity in healthy young adults. Environ Health Perspect. 2007; 115 (12): 1732–1737. https://doi.org/10.1289/ehp.10294 PMID: 18087591

Chuang KJ, Chan CC, Su TC, Lee CT, Tang CS. The effect of urban air pollution on inflammation, oxidative stress, coagulation, and autonomic dysfunction in young adults. Am J Resp Crit Care Med. 2007; 176(4): 370–376. https://doi.org/10.1164/rcrm.200611-1627OC PMID: 17463411

Patrignani P, Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers. 2005; 10 Suppl 1: S24–S29.

Morrow JD. The isoprostanes—unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr Pharm Des. 2006; 12(8): 895–902. https://doi.org/10.2174/13816120676055985 PMID: 16533158

Laskin DL, Fakhhrzadeh L, Laskin JD. Nitric oxide and peroxynitrite in ozone-induced lung injury. Adv Exp Med Biol. 2001; 500: 183–190. https://doi.org/10.1007/978-1-4613-0667-6_24 PMID: 11764933

Yu AP, Tam BT, Yau WY, Chan KS, Yu SS, Chung TL, et al. Association of endothelin-1 and matrix metalloproteinase-9 with metabolic syndrome in middle-aged and older adults. Diabetol Metab Syndr. 2015; 7: 111. https://doi.org/10.1186/s13098-015-0108-2 PMID: 26692905

Calderon-Garciduenas L, Vincent R, Mora-Tiscareno A, Franco-Lira M, Henriquez-Roldan C, Barragan-Mejia G, et al. Elevated plasma endothelin-1 and pulmonary arterial pressure in children exposed to air pollution. Environ Health Perspect. 2007; 115(8): 1248–1253. https://doi.org/10.1289/ehp.9641 PMID: 17687455

Bossard M, Pumpol K, van der Lely S, Aeschbach S, Schoen T, Krisai P, et al. Plasma endothelin-1 and cardiovascular risk among young and healthy adults. Atherosclerosis. 2015; 239(1): 186–191. https://doi.org/10.1016/j.atherosclerosis.2014.12.061 PMID: 25617859

Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007; 76(1): 8–18. https://doi.org/10.1016/j.cardiores.2007.06.004 PMID: 17617392

Pernow J, Shemyakin A, Bohm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci. 2012; 91(13–14): 507–516. https://doi.org/10.1016/j.lfs.2012.03.029 PMID: 22483688

Barath S, Langrish JP, Lundbäck M, Bosson JA, Goudie C, Newby DE, et al. Ozone exposure does not impair vascular function or affect heart rate variability in humans. Toxicol Sci. 2013; 135: 292–299. https://doi.org/10.1093/toxsci/kft157 PMID: 23872581

Kahle JJ, Neas LM, Devlin RB, Case MW, Schmitt MT, Madden MC, et al. Interaction effects of temperature and ozone on lung function and markers of systemic inflammation, coagulation, and fibrinolysis: a crossover study of healthy young volunteers. Environ Health Perspect. 2015; 123(4): 310–316. https://doi.org/10.1289/ehp.1307986 PMID: 25514459

Strak M, Hoek G, Steenhof M, Kllinc E, Godri KJ, Gosens I, et al. Components of ambient air pollution affect thrombin generation in healthy humans: the RAPTES project. Occup Environ Med. 2013; 70(5): 332–340. https://doi.org/10.1093/occmed/kct023 PMID: 23378445

Liao D, Heiss G, Chinchilli VM, Duan Y, Folsom AR, Lim HM, et al. Association of criteria pollutants with plasma hemostatic/inflammatory markers: a population-based study. J Expo Anal Environ Epidemiol. 2005; 15(4): 319–328. https://doi.org/10.1038/sj.jea.7500408 PMID: 15536489
60. Goodman JE, Prueitt RL, Sax SN, Pizzurro DM, Lynch HN, Zu K, et al. Ozone exposure and systemic biomarkers: Evaluation of evidence for adverse cardiovascular health impacts. Crit Rev Toxicol. 2015; 45(5): 412–452. https://doi.org/10.3109/10408444.2015.1031371 PMID: 25959700